Reddit biotech plays. 18K subscribers in the Biotechplays community.

Reddit biotech plays A buyout of a Biotech company is what every Biotech investor is hoping to achieve: it is the holy grail of Biotech investing. Let me know what you think! Special Purpose Acquisition Companies (SPACS), Units, Warrants and the best DD on Reddit. S. Letter 003: The Roaring 20’s . r/biotech: News about any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify Bio-mimicking nature proves out a worthy anti-aging solution https://glycoprotemim. These are the most mentioned stock tickers on r/Biotechplays. 18K subscribers in the Biotechplays community. These are some of my plays. May 6, 2022 · Warren Buffett has a saying about the stock market and investing in general: “Be fearful when others are greedy and greedy when others are fearful. Some of the Alzheimer plays are interesting (SAVA, AVXL, ANVS), but they have institutional ownership below 50%. com. Witkowski, Director, Pancreatic and Islet Transplant Program at the University of Chicago, is scheduled to deliver his presentation, Islet Allotransplantation Into Pre-Vascularized Sernova Cell Pouch™ – Preliminary Results From The University of Chicago, to more than 600 transplant professionals as part of Get the Reddit app Scan this QR code to download the app now. I have worked in the clinic, academia, and for biotech startups before switching to investing full time. I guess from their website "All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. BBI, HTGM, AFIB, just to name a few of my own positions that have exploded in the last week. Made me realize they super volatile and you really have to luck out to win this , even if you play big early on you need to be lucky not to hold till dilution or bankruptcy. They are often years or even decades old and none of the clinical trials worked as planned. The company halted its Wilson disease program, ditched dozens of its machine The sell-off in biotech has gone too far, so how do we take advantage of this? What are the biotech stocks that can position us for outsized gains in the future? Are you looking at these? Discover 3 Biotech communities on Reddit, like r/biotech, r/biotech_stocks, r/biotechnology and more. Makes sense that after the initial excitement, investors are realizing they are more of a mid-long term play. " So I think it's equivocal on whether it's truly impactful. me for the same reason. And not so easy to pin down reasons for, as fears like short-term strong legislation or a strict FDA chair have been squashed. 0 million and $40. Members Online. Got Biotech, Plays without Combat extended because 1. When q4 comes out I would pay attention to the financials because this could get a reverse split to stay afloat. 19K subscribers in the Biotechplays community. It follows the portfolio of a guy named Ohad Hammer, who discusses what he buys or sells Mar 22, 2021 · We were just discussing in the discord- the risk reward is crazy good. I see these very same stocks getting purchased by insiders. heavily undervalued - new clinical data coming on January 15 "Dr. I do not expect a great turnaround in one quarter (Q2 tomorrow is April to June, New CEO started May 5th and didn't make changes until June), but if they could even maintain 400 prescriptions per Biotech Street by COSA Media is a Substack subscription newsletter that provides product assessments on publicly traded Biotech, Pharma, and Healthcare companies. 5% yearly revenue growthprojection. It is a solid play, a disruptive technology. Jan 31, 2022 · In this week, we're back to questions on whether the bottom for the XBI is in. The difference is that 217 works as quickly as 3 days. While lurking into this group, I got some basic info like checking biopharmcatalyst calendar etc. Shorting every Biotech Startups During Clinical Trials of phase 2 and 3 - How dumb is it? Is it a bad idea to short positions on biotech startups when they announce clinical trial results? And if so, why? I recently came across these stats that seem to suggest most Recent orders include Canada, Australia, Japan, Florida (Govenor ordering direct from GSK), UAE, EU commission etc, leaving VIR in a strong financial position with strong partnerships. Hi, still new to making biotech plays. This is a sanctuary for those who appreciated the original WSB vibe but prefer a refined focus, steering clear of international and meme stocks. Dec 1, 2020 · Potential 20bagger: SVA. Spruce is a small biotech committed to transforming the lives of patients living with rare endocrine disorders. Not investment advice. Longevity companies are probably the highest risk, yet even higher reward (actually, highest reward, it's not even close) sector of biotech. What I like is the business model. The financials are solid. In its most simple form, for a one product, one indication biotech. Risks-Ordinary for a biotech play. Jun 11, 2024 · Welcome to r/KULR, your hub for investors passionate about KULR Technology. Clinical results can be negative, others can do it first or better etc -I'm not super fond of a 35 year old female ceo, screams theranos to me but the other players are all veterans -They can dilute further. In the waning days of 2021, I began a Apr 29, 2021 · Excellent question, I was thinking of making my next guide be about this topic actually haha. I'm a relatively new investor and am looking for a low entry biotech with a %500 Open menu Open navigation Go to Reddit Home. I can't for the life of me figure out why it hasn't run yet. I personally have SNDL for no other reason than it is a good price point for retail traders to run it up on approval. Spruce’s wholly-owned and only product candidate, tildacerfont, is a CRF1 receptor Alchemists Hate This One Simple Trick! Turn 8¢ into $1 by 2025 with SELLAS Life Sciences, a Biotech with a Phase 3+EAP Drug Nearing BLA Submission & Commercialization. ”. A ridiculously high signal to noise ratio in useful biotech-related information. There are companies now that are preclinical, and IPOing at extremely high valuations pre-revenue. Other than holding Buffett's fav stocks like Coca-Cola (NYSE: KO) Excellent question, I was thinking of making my next guide be about this topic actually haha. Feb 5, 2021 · Yes you are correct. I've been researching last couple weeks what are the most promising drugs in the Alzheimer's / Parkinson's pipeline. That was in 2014, before they had trial results, and they bought a 15% stake for $35 million, a $233 million valuation for the whole company. Nov 9, 2021 · Bluebird is focused on 3 areas- CALD, SCD, TDT. Mar 13, 2024 · Now that I am finishing up my PhD in molecular biology at Harvard, I realize I have seen a lot of great science. Citius Pharmaceuticals at end of month because that's when they share their Phase 3 data. Value creation takes time and while companies will need to take advantage of stock price with fund raising, it's barely discussed on a day to day, month to month basis. I believe for a biotech company that IPO'd only two years ago, that the success of Sotrovimab highlights the potential of their future pipeline. It monitors several news sources like FDA approvals, Twitter, SEC filings, etc, and filters important news. Open menu Open navigation Go to Reddit Home. Sometimes I’ll play the odds on pivotal trial outcomes via options (eg I think a stock is pricing in a 75% chance of success but historical data indicates it should be 40%). Roger that. This is for a smaller biotech (900M cap) with almost no retail discussion on any board. January 3rd, 2022 -- in their S-1, they talked about the data they had so far and announced they were planning on getting FDA approval for their drug for ALS later that year. Like I said, there are other better options but if I only had $1k and a year to play with that's what I would go with. com isn't at all like techcrunch so not really answering your question, but they do have material that informed some plays Reply reply Top 5% Rank by size Seen some posts about this elsewhere and some good DD. Currently down $55,000. It was "safe" based on all analyst price targets and preliminary drug studies. A due diligence that grossly overlooks any risks of the company and overplays its chances of success is likely a chance to pump and dump stock and shouldn't be posted in the subreddit. You can’t swap them interchangeably. AGEN (PD1, ILT4) has 1 partnership and good cash. ATNF in between catalysts because it has a massive cult-like following and seems like a good company aswell. But once phase 3 clinical trial failed short stock dropped 85% in 2 minute interval. Arbutus Biopharma has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Posted by u/Kriezler - 5 votes and 1 comment 47 votes, 51 comments. This designation is typically seen in serious, life threatening diseases where there are limited treatment options (cancers, HIV, rare diseases). Long read tech and illumina read tech have different goals. Did it suffered it and trying to make some sense while trading now. May 22, 2023 · IOVA’s BLA application is due to be approved this week. Clinical trial in Paris, with 20 women showed the following54% decrease in inflammation, 54% decrease in skin oxidation while boosting skin density and collagen by 37% in only 3 months. Like all 3 or just put in xbi Reply reply Global_Style7956 • Agree on VRTX, and they are looking pretty cheap right now after EPS miss. Get app Get the Reddit app Log In Log in to Reddit. I approach biotech investing from a finance background and know I will never have an edge at evaluating the science. Stryker is a unique play for biotech like. I know some fields are bigger than others, but interested in your takes. When was the last time that Coca-Cola had to prove that it was good for you. On the other hand I don’t really follow your reasoning. It's not just television, it's a way of life. General Overview. Apr 20, 2023 · Here is a list of stocks that have seen big price movement recently with continued upside potential. Funny that FBRX screenshot was mentioned. 60 and clinical data expected before the end of the year, Gossamer is also a very attractive tax bounce play assuming Aug 18, 2020 · Well, Novartis did end up being prescient in their decision. I'm trying to do some DD on CAR T-cell therapy companies, and wanted to see if there was a source that lists similar companies, or companies within the same field. Then, I watch to see if they crash back down right away or look like they will keep moving. Nov 21, 2023 · This subreddit is for all those interested in working for the United States federal government. Dec 22, 2019 · Sure. Have lost a lot of money in the past on this bios . None of the companies I worked for went anywhere. Biotech Plays Stock Pick 2022 Contest Winner! Huh?!? is probably your reaction seeing this post. Small profit is still profit. 4, then gets his 20 shooting skilled pawns annihilated by Neanderthals with hammers Story Seriously I miss Combat extended Welcome to Destiny Reddit! This sub is for discussing Bungie's Destiny 2 and its predecessor, Destiny. Here’s a short commentary from my girl Cathie Wood today after the drop: Twist Bioscience (TWST) fell approximately 17% on Friday after reporting fiscal first quarter results that outperformed analysts’ expectations on both the top and bottom lines but leaving 2021 revenue guidance unchanged. r/Biotechplays A chip A close button. These insane 100% gap-ups are institutions taking positions. Food and Drug Administration in mid-2022. It is definitely the case in the volatile stem cell and cell therapy arena. New to reddit Reply reply Keep buying, the market has massively underpriced FREQ based on their potential. Was 85 it? Do we not have to worry about rising fed rates, a half functioning FDA without a chairman, omicron slowing down trials, elective surgeries, East European instability, some mediocre trial results, and a string of clinical holds dragging us further down than the -50% we're at? May 11, 2022 · I think it’s just the macro market conditions, we rarely see such an easily fixable CRL, it feels like they should get approved next week. Due Diligence, and I’m starting a weekly series where I am looking at the top shorted biotech stocks in the world to try and find value. The week started of great but it closed red. Any thoughts from any of the more experienced folks here? Have begun a deep dive into Krystal Biotech. They may have to or they may not. Feb 2, 2023 · Looks like a pretty high cash burn at 30mill last quarter and about 150 cash on hand. Iovance Biotherapeutics . That was my last and only volatility play last year in a single drug candidate biotech. My first job was 2 weeks at a very small biotech. Or check it out in the app stores &nbsp; No BS trading and fundamental analysis of biotech stocks. Very few have actually dug into the data to understand why their phase 2a trial failed. However markets really wanted some sort of data indicating more. Aug 8, 2023 · View community ranking In the Top 5% of largest communities on Reddit. Gene/Cell therapy trials are expensive (~200k per subject) and many factors play in the results. You probably alrdy have a fair idea of what abcl does - an AI powered drug discovery platform. The amount of shorts and small float mean the set up is really sweet for a Apr 13, 2021 · Twist Bioscience (TWST) - great biotech play and also working with Microsoft on the future of data storage. Be professional, humble, and open to new ideas. This subreddit is a place where high income professionals of all types can ask, answer, discuss, and debate the personal finance and investing questions specific to our unique situations without being criticized, ostracized, or downvoted simply for View community ranking In the Top 5% of largest communities on Reddit. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. Dec 16, 2022 · hello biotech traders and investors, Does anyone know if institutional ownership helps predict approval vs the dreaded CRL? I'm looking to play the upcoming PDUFA in TGTX and the institutional ownership is good (~ 76% of the float). The data was positive, and combined with the previous study, shows significant efficacy. Sep 5, 2018 · Posted by u/cashbylongstockings - 3 votes and 22 comments Mar 7, 2021 · I feel like this is a stock to keep an eye on. Last report showed success in producing insulin for 9 months so 1 year will be a big milestone and a big increase in value again. Phase 3: regular population, big trials. V. Most of my day trades are biotech. So I would assume you guys on biotech plays are well aware of ATNX and their upcoming PDUFA which seems likely to be approved (yeah I know everyone thinks that about every PDUFA but this had very successful phase 3 trials), so why have I only seen one mention of it? Welcome to the Crown Electrics new Reddit🚀 New CRKN Reddit was made as a The official subreddit for discussing Idle Champions of the Forgotten Realms, a Dungeons & Dragons strategy video game that brings together D&D characters from novels, adventures, and multiple live streams into a single grand adventure. 50 CAD Sep 10, 2021 · Apellis just got crushed in a typical biotech story as old as time. 10:02 AM EDT, 06/29/2021 (MT Newswires) -- DiaMedica Therapeutics(DMAC) has an average rating of buy and price targets ranging from $14 to $32, according to analysts polled by Capital IQ. As much as I respect FATE, I'm heavy into IBRX tho. There is no shying away from that, good news is few and far between. Open Reading Frame is my favorite blog. DD Jan 14, 2020 · Nice catch. Selloffs on good news, selloffs on bad news, selloffs cause it's Tuesday. Because the drug is a quite special one. So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm: 180 << All Reddit Analytics. It’s tough to predict exactly when an acquisition will occur but here is a list of stocks that I along with many others in the general market believe will see a buyout very soon! #1: Nkarta Inc. st indicated 33. I usually run a screener for stock under $15 that have gapped up 10% or more before the market opens. 📈 May 16, 2021 · FATE's work in NK cells proves the theory that NK cells work in ways just as good as CART-cells without all the side effects. Apr 30, 2021 · Hi All, I'm new to Biotech industry (not new to stock market though). It trades ~$1. Top Mentions — Timeframe Subreddit . Dec 16, 2022 · Welcome to r/wsbafterhours, where the spirit of bold market plays lives on. This is kind of the standard of “life” as any biotech company. There is a difference between due diligence and selling a stock like it's free money. Rather than complain, there's still a recipe behind the last few weeks' runners to figure out and apply. I am currently researching SIGA, BAVA, EB and GILD. Is it Also, weed could be federally legalized soon. Watch free episodes and marathon streams on adultswim. Evaluate Vantage is my favorite news site. The first is called DECIPHER which identifies targets through a simultaneous knockout of two genes where one gene is a known tumor suppressor and biomarker and the other is a potential synthetic lethality target. I'm a novice at Biotech stocks. Shorting every Biotech Startups During Clinical Trials of phase 2 and 3 - How dumb is it? I'm pondering something and would love your insights. CART-cell therapy has just terrible side-effects. March 6 until 9 there is a conference for Sernova to update clinical trials it will be 1 year from first human transplant. This is original analysis from academically affiliated medical doctors and researchers, agnostic to the biases of financial services equity analysts -- and faithful to nothing more than evidence and intuitive May 1, 2023 · A buyout of a Biotech company is what every Biotech investor is hoping to achieve: it is the holy grail of Biotech investing. (NASDAQ: CTXR) has an upcoming PDUFA date set for July 28, 2023, for Denileukin diftitox (E7777) — (I/ONTAK) which treats CTCL non-Hodgkin lymphoma. Not a big fry, medium size fry, but without that 1 p3 hiccup where red eye didn't hit primary endpoint this would still be a great bet. Exemplary scientific advisory board with world renowned key opinion leaders Collaboration with Parexel Biotech to conduct Phase 1b/2 clinical trial in Chron’s patients Biotech companies are now using IPOs to fund drug development and IPOing early. My investment style, and opinion, is based on equal parts experience, research, and stalking C-suite. Members Online • GoldMining5 . Jul 5, 2021 · Similarly positioned and pipeline biotech stocks either sold for 2B (kymab, fprx) or currently above 1B in marker cap (AGEN, NGM). ? Just curious what the community thinks, I'm leaning towards only enabling Biotech for my first run-through at the very least. The value proposition for investing in Unity Biotechnology can be concisely summarised by the breakthrough preclinical data from the Mayo Clinic. I would imagine you could have both of them enabled, but the question is do I want to. No one has been really expecting much from the data (pretty low IV from the options considering this is a big readout), super hard to treat indication - many failed attempts in cirrhosis. They also point out that earnings are forecast to decline (their analysis) of 18. Jun 7, 2023 · This answer is super diverse. Simplywall. Deep Dive into CRHC, Gary Cohn's companies Apr 28, 2021 · New to Reddit so regrets if not a good post. difficile infection (rCDI) predicts that FDA will approve this treatment (probability >95%). As a part time biotech analyst for an investment fund in the Boston area, I have evaluated a lot of biotech companies . The Phase 3 results about recurrent C. There is no data to come till the 19th. I'd recommend doing a little googling. May 22, 2023 · A Cheap But Volatile Biotech Play Upcoming! Due Diligence (DD) Citius Pharmaceuticals Inc. That's the same market cap as today - it would have been dead money for Novartis until now. Edit: they did a public offering after q3 earnings for another 75 mill so should have an ok cash runway for this year. Yeah, that's a good point. The recent data read on OTX-2002 showed that the mechanism of how their Omega platform worked. I have worked on 2 gene therapy and 1 cell therapy biotech/startup. Fundamentally I agree that especially PacBio is a steal at the current price and a lot less risky than most sold off biotech plays. Feb 9, 2021 · Legend Biotech Corp. Since the application process itself is often nothing short of herculean and time-consuming to boot, this place is meant to serve as a talking ground to answer questions, better improve applications, and increase one's chance of being 'Referred'. 9 percent per year forthe next 3 years. Massive overreaction to a perceived bad trial result. There’s some products that have been waiting for 510K approval even longer than Endra. For abcl, the tam for monoclonal antibodies in 2030 is projected to be around $350+ billion, with a cagr of about 10% ish from the $146bil in 2020. We are also very bullish on the stock and believe this company will grow rapidly in the coming years. The earnings are tomorrow, and shorts are going hard at it, including a $300,000 dark pool trade. The idea is that the parent company is capable of amassing and managing the funds necessary to bundle and launch companies/assets in an efficient manner. 0 million upon the The week in which the JNJ vaccine (almost certainly) gets approved, SRPT's casimersen possibly gets approved, and we get to see if XBI continues its The market is still quite volatile. Here, we’re all about sharp analysis and strategic moves in the market, building on a legacy but charting our own course. X4 Pharmaceuticals Biotech Play Discussion I have created bioalert. Wondering what this groups thoughts are on chances of application approval and subsequent May 19, 2021 · I was just watching some youtube pundit pour over Burry's 13F and I noticed he sunk about a million into ARPO. 0 million and $25. (checked your website) Myostatin inhibitors are really cool, and it'd be very interesting if they can make one with terrible side effects. Who is out there buying and selling in this information desert. . It absolutely has not been rejected. Now that I am finishing up my PhD in molecular biology at Harvard, I realize I have seen a lot of great science. / SEOVF in the US - cheapest biotech play on the venture - functional cure for chronic diseases like diabetes type 1, hemophilia etc. Other than that, my plays for April are: CVAC before 4/19 due to potential approval by CHMP. If you like this type of DD, click on my profile and give me a follow! For DD not seen on Mar 13, 2021 · Not a biotech expert but I was looking into PCRX and I'm feeling "confident?" that their upcoming PDUFA date (3/22/21) will go well. Discerning types of Biotech Plays: Big Bail (BB) There is nothing else in the stock market quite like biotech stock. Posted by u/Brilliant-Rub9815 - 12 votes and 30 comments Phase 2: “Is there enough measured benefit to test this on more of the public”. As a hiring manager there are lots of reasons for this. Jun 30, 2022 · I've been acquiring this since last summer in the $4s, rode it up to $15, rode it back down to $3 lol. What is reddit biotech? News and requests about any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify Hi, I’m Dr. Please read the sidebar rules and be sure to search for your Get the Reddit app Scan this QR code to download the app now. Biotech data readouts in Phase I-III, and especially trial stoppages have an inordinate amount of sway in a stock. Here’s why: Sep 4, 2023 · Is it a bad idea to short positions on biotech startups when they announce clinical trial View community ranking In the Top 5% of largest communities on Reddit. Roth Capital Adjusts DiaMedica Therapeutics' Price Target to Mar 19, 2024 · Because I’ve been in this space for over a decade. Back in January 2019, Moderna, whose entire drug Jun 20, 2024 · A community of individuals who seek to solve problems, network professionally, collaborate on projects, and make the world a better place. Spruce’s wholly-owned and only product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult patients with classic congenital adrenal hyperplasia (CAH). 1-2 point reduction in HAM-D from placebo is the norm in psychiatry and SSRIs. (NASDAQ: NKTX) Jun 30, 2022 · Here's my own personal speculation: Biotech is criminally undervalued and big money is quietly putting their chips on the table. I’m currently holding over 10K shares. Biotech focused weekly newsletter. Our community supports side hustles, small businesses, venture-backed startups, lemonade stands, 1-person-grinds, and most forms of revenue generation! Dec 4, 2021 · Even with beloved Tech - they do this, but it tends to be on a longer cycle. These markets Reply reply Dec 28, 2023 · Yessir, posted about it here a few years ago. Aug 20, 2021 · Hi, I’m Dr. Welcome to r/wsbafterhours, where the spirit of bold market plays lives on. It depends on the timeline Astellas proceeds with and the milestone payments due to FREQ. Earlier this year, speculators on platforms like Reddit’s r/WallStreetBets sent scores of small biotech stocks “to the moon” on little more than hype. From their 8k - "we would receive development milestone payments of $65. CAR-T needs a lot of work to start making an impact in solid tumors. Their first phase 3 clinical trial is due for top line data this quarter. The missed data was barely statistically insignificant, but actually proves a few things: Sep 25, 2020 · Welcome to r/wsbafterhours, where the spirit of bold market plays lives on. I am not an investment advisor, do your own due diligence. It carries out its operations through the North America, and China geographical segments. operates as a development-stage biopharmaceutical company. BioSpace. Not sure how large the market is -- Dupixent, steroids, and JAK inhibitors have taken up quite a lot of market share already. Most gene therapies involve an adeno-associated virus vector platform; however STAR-D utilizes the herpes simplex type 1 virus to enable gene transfer. 🔬🚀 Our newsletter is your one-stop destination for all things biotech, and we're here to share why our content is a must-read for the Substack community. The hold up, best most of us can tell is Covid. I've decided to try my hands in Pdufa Runup. CALD and TDT (in the US) are relatively tiny markets so ignore those for now (but sidenote- Bluebird Aug 4, 2021 · Just wanted to provide an update to my post. ARDX 4/29 for PDUFA. Apr 18, 2022 · Hot biotech play: buy $500,000 of XBI, rent a cabin in the woods with no internet and live off the land costing $5000 for a year, come back and profit. Sep 24, 2021 · Letter 002: Discerning Types of Biotech plays. But as a basic rundown: typically biotech valuations use a calculation called risk-adjusted net present value. Illumina is high accuracy. Once we remove the plaque targeting companies (Biogen, AC Immune, Eli Lilly), it seems like at least in public trials there's just a few inflammation pathology focused companies that remain such as Denali (recent track record has been a little a limited), Looking forward to the report on SRRK. The estimated revenues for the lifetime of the drug are calculated and then a discount rate is applied. And both well beyond 1B market cap. The drug treats complex Urinary Tract Infections (cUTI) and the study design is complex and highly detailed. Get app Get the Reddit app Log In Log in to Reddit at $0. I've got into XFOR for FDA approval which is expected Tuesday and a possible Priority Review The data looks good. - 61m market cap - German analyst target price 5. It's only $17 per month, but doesn't seem very thorough. And, yes I realize that a million out of a billion dollar fund is, well, 1/1000th of that fund, but I think the way Burry plays this game involves making significant gains from small holdings. And jazz just bought gw pharma so they are making the cannabis play. If these are 2nd/3rd Gen CAR-Ts, we might not see good, broad solid tumor results until 6th/7th Gen. I do like it when there’s no run up though, the pop will be bigger. These biotechs have ups and downs, sometimes at the same time. Based on As others have noted on previous threads, he is one of the highest performing (if not the highest) biotech investors of all time. While the technology sounds promising. There are even companies that are barely into human studies become public then get acquired (M&A likely to increase in the 2020s - read here about it ). Omega Therapeutics, Inc. You wouldn’t use high precision medical tools for cooking, and you wouldn’t use chef’s knives for surgery. To get real-time mobile notifications if there is an important event that can change the price of the stock. But, now, online chatter isn’t enough Today, Deep Genomics has zero drugs in clinical trials and many of its plans have blown up. Third was a small biotech- 2 months and my most recent role was 3 months from application to offer. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The market and funds are overreacting. I was lucky to exit at $4. Nov 23, 2021 · In case you were wondering why this sub has been a bit quiet lately, I think this may be playing a major role :) But yeah, pain. May 12, 2023 · I‘m trying to collect some data about historical PDUFA dates. Play the run ups, hold through FDA decisions, double your money or lose it all! /r/bioinvesting is a subreddit where we can all exchange ideas about investing in biotechnology/pharma companies and hope to strike gold! Sep 17, 2021 · I always look for risky plays, because that is where you only need one or two to play out. Looking to learn what's your Feb 12, 2021 · Trading at $4 but they own the patent on the mRNA delivery vehicle that Moderna uses in its entire drug portfolio. r/Biotechplays: No BS trading and fundamental analysis of biotech stocks. This is purely anecdotal, but I attended one of the big dermatology conferences in October (EADV Madrid) and I remember daxi making a pretty big splash with a very impressive presentation of their trials. Ideaya has data from two proprietary platforms for generating synthetic lethal targets. Short version is that drugs can be approved early when the FDA designates the drugs under Accelerated Approval. As someone that has helped turn around an under-performing company previously, and it ended in a very successful buyout. EYPT: When I first called out this stock, it was trading only a few cents away from 52-week lows indicating that it was severely undervalued and a reversal was due soon. 0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100. Is there any website where i can find these dates from 2022, preferably including the actual date of approval/CRL? Just checked some (biopharmacatalyst e. The FDA approval is just the tip of the iceberg with this one. Heat shock protein 70 activator/amplifier, which may have more applications than just ALS, also in mitigation of Huntington's, Alzheimer's, Parkinson's (neurodegenerative diseases Aug 14, 2020 · Spero Therapeutics is a clinical stage pharmaceutical company targeting treatment of multi-drug resistant(MDR) bacteria. Today was a very good day for Sernova. Jul 25, 2021 · Welcome to r/wsbafterhours, where the spirit of bold market plays lives on. The biotech market has been brutal. Entrepreneurial success in biotech deals; CEO is co-founder, Synergy Pharma; Executive Chairman founded and chaired two biotechs with $2B+ market caps. Welcome to the official subreddit of the PC Master Race / PCMR! All PC-related content is welcome, including build help, tech support, and any doubt one might have about PC ownership. Biotech Investing is largely risky. I would look for higher stability given the volatility in the market right now and available cash flow, so TNXP is not something I'm too interested in personally as with rate increase environment, speculative plays Welcome to r/wsbafterhours, where the spirit of bold market plays lives on. KRYS' main IP is its STAR-D gene therapy platform. Here’s why: I like the pick and shovel biotech plays. Jun 18, 2020 · The first monoclonal was even earlier than that! Ortho’s OrthoClone OKT-3 was a monoclonal antibody approved back in 1986! Anyway, that’s not really a problem—antibodies are great because they’re straightforward to discovery, test, and commercialize. Many stocks with good news pre-market and a market cap of max a few 100m still runs like crazy though. So I have been day trading and swing trading biotech for a few years with decent success. Or check it out in the app stores &nbsp; risk in biotech should solely be estimated on scientific merit, trial results and competition. Second was at a large bio-pharma and that took about a month. Just my novice thoughts. However, I don't think biotech companies are great companies to play short squeezes. Dive into discussions, news, and analyses about KULR's innovative thermal management solutions and space technology advancements. Subscribe to Max and Hulu for full seasons to a whole lotta shows. About 75% institutional ownership. I got the paid subscription to Biopharmcatalyst about a year ago. I love flier biotech plays, because when they work, they really There's a few of these newer large biotech that consists of multiple subsidiaries. r/Biotechplays Sentiment and Mention Tracker. This is original analysis from academically affiliated medical doctors and researchers, agnostic to the biases of financial services equity analysts -- and faithful to nothing more For orphan drugs safer plays like vertex pharm. With that being said, I'm excited for 2022, time will tell how it plays out. Oct 20, 2022 · With the Biotech release tomorrow I'm a little confused with how expansions work. g) and either are Sep 20, 2021 · "Seres expects to file a Biologics License Application (BLA) with the U. Long read is low accuracy. Jun 29, 2024 · All kids out of the pool! This is the unofficial subreddit for for the life-changing pseudo-network [adult swim], which airs every day from 5PM - 6AM on Cartoon Network (EST/PST). Exchange Traded Financial Options -- Options Fundamentals -- The Greeks -- Strategies -- Current Plays and Ideas -- Q&A -- **New Traders I personally am not touching ph1 biotech stocks anymore, as they trade totally arbritarily and are very hard to make sustained multibagger gains from as a retail trader. NGM similar to JNCE and is entering into ILT4, and has 1 partnership, 400M cash. Due Diligence, and this is part of my weekly series where I am looking at the top shorted biotech stocks in the world to try and find value. Fields aided by an improvement in technology such as biotech, as opposed to areas such Feb 24, 2021 · You can play the catalyst game with biotech investments, but most companies, nor employees care about short term anything. Jun 22, 2024 · Spruce is a small biotech committed to transforming the lives of patients living with rare endocrine disorders. I would say Biotech will break out, and the question is when not if. Nov 8, 2023 · No BS trading and fundamental analysis of biotech stocks. But Caribou Bioscience (CRBU) is where I’d put all my money. They have some competition in STAT News herebut most of STAT is behind a paywall, and this is all free :) . I've been noticing that alot of PDUFA dates which I find on the free sites aren't even listed on the paid version of Biopharmcatalyst. (NASDAQ: NKTX) Chasing short squeeze has become a very fun sport that many traders like to play, and it is a fair game that punishes people who over-stayed on consensus / secular trades. They have a full schedule for reviewing tons of products and each division makes the announcement when they are comfortable that the data supports safety and efficacy. For those interested I wrote about this in-depth recently (check my post history). Sep 11, 2022 · So much has happened in Amylyx Pharmaceuticals this year, that it's hard to remember that they only IPO'd this year. IBRX will have a product to market before FATE does because IBRX is further along in clinical trials. Unfortunately though my average is around $11 so Im down pretty significantly. Other examples include BridgeBio Pharma or Fortress Biotech. I think this product could bump the share to at least $2-$3 perhaps more making it a very profitable play. Letter 004: Biotech Venture Capital and how it affects your investments. They have already been approved for this drug (Exparel, opioid-free pain control) before, and now they are looking to use it on child patients. " Company pps after BLA will be at least $10. Both are usually blinded (nobody knows who gets the real meds vs placebo), results are measured against a placebo (not medicine against no medicine given), many more subjects tested, especially phase 3, (this gives the study its power of measurement in the Biotech Street by COSA Media is a Substack subscription newsletter that provides product assessments on publicly traded Biotech, Pharma, and Healthcare companies. The market was overinflated due to Monetary Policy, VC inflated IPOs (written extensively about here in Dr. Hopefully they won't after how it PLATFORM. No BS trading and fundamental analysis of biotech stocks. Reply reply Unlucky-Prize Lol he’s right, but to expand a bit on this point: The FDA doesn’t have a set time of day for every drug. Multiple Myeloma biotech Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. This is due to the fact that the light chains play an important role in forming antibodies against many different types of antigens (foreign substances) and in order to be able to do that they need to be able to adopt many different types of configurations under normal conditions (something that’s known as V(D)J gene recombination). I remember making a mental note to look into the company as a potential long term investment opportunity and this actually reminded me of Jan 1, 2023 · View community ranking In the Top 5% of largest communities on Reddit. Biotech x10 plays? First we have Pliant Therapeutics Inc (Nasdaq:PLRX) which rallied 159% on Jul 11 after the company announced positive results from Stock is priced like a clinical stage biotech when it is a commercial stage biotech (NCCN recommendations, FDA approvals, and favorable EU approval on STORM data, with BOSTON approval expected soon). I emphasise the reward as truly unprecedented and anyone About as pure of a biotech play as you can get, with so many variables, so much volatility (300% upside/90% downside), and lots of reasons to be both bullish and bearish on this readout. This felt inevitable. Jun 18, 2023 · View community ranking In the Top 5% of largest communities on Reddit. mcdpiz nszpi zwwof skooza ggv kpdf fnyse evxmp jzmrh upgntp